Enzo Biochem said this week that it has entered an agreement to purchase a nearly 36,000-square-foot commercial facility in Farmingdale, New York, that it anticipates will enhance its ability to produce and distribute a growing portfolio of molecular, immunohistochemistry, immunoassay, and immune-oncology products and services.
The building, adjacent to the company’s Long Island campus, expands the infrastructure needed to produce and distribute its expanding diagnostic platform products and related services, including automation-compatible reagent systems and associated products for sample collection and processing through analysis. The new facility also provides more space for production of its development-stage clinical candidates, including Enzo’s proprietary sphingosine kinase 1 inhibitor, SK1-I, which is being investigated for potential applications in oncology and autoimmune diseases.
In connection with the acquisition of the new facility, the Town of Babylon Industrial Development Agency has committed to providing multi-year tax abatements and additional incentives, Enzo said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.